Small Cap Losers: SESN, PCVX, MRNA
4:00 pm Wednesday, August 18th, 2021
Sesen Bio Inc (NASDAQ:SESN) continued volatility following co’s receipt of a Complete Response Letter from the FDA for Vicineum. A report from Stat News today highlighted “misconduct” and “worrisome side effects” in co’s clinical trial for Vicineum. Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.
Vaxcyte Inc (NASDAQ: PCVX) pulls back on moderate volume after reaching its highest levels since March in recent sessions. Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine.
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) reported top-line results from its Phase 2 trial evaluating adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex. Among results, the primary endpoint showed a median 16.6% reduction in 28-day seizure frequency relative to baseline in TSC patients, and 30.4% of patients achieved a 50% or more seizure reduction. The FDA has granted orphan drug designation to ganaxolone for treatment in TSC.
